Takeda’s Ninlaro Misses Mark In Transplant-Ineligible 1L Myeloma
Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.
You may also be interested in...
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.